Lupin launches Ipratropium Bromide Nasal Solution in United States

04 Jul 2025 Evaluate

Lupin has launched Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, in the United States. Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06% are bioequivalent to Atrovent Nasal Spray, 0.03% and 0.06%, of Boehringer Ingelheim Pharmaceuticals, Inc.

Ipratropium Bromide Nasal Solution (Nasal Spray) 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children aged 6 years and older. Ipratropium Bromide Nasal Solution (Nasal Spray) 0.06% is indicated for the symptomatic relief of rhinorrhea associated with the common cold or seasonal allergic rhinitis for adults and children aged 5 years and older. Ipratropium Bromide Nasal Solution (RLD Atrovent) had estimated annual sales of $63 million in the U.S. (IQVIA MAT May 2025). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.

Lupin Share Price

2178.75 2.50 (0.11%)
19-Jan-2026 15:17 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1674.85
Dr. Reddys Lab 1165.40
Cipla 1391.40
Zydus Lifesciences 881.95
Lupin 2178.75
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×